We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-15.96%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$478M
AUM Growth
-$169M
Cap. Flow
+$26.7M
Cap. Flow %
5.59%
Top 10 Hldgs %
73.56%
Holding
41
New
2
Increased
3
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$21.7M
2
CTNM
Contineum Therapeutics
CTNM
+$9.48M
3
CRGX
CARGO Therapeutics
CRGX
+$5.59M
4
CYPH
Cypherpunk Technologies Inc
CYPH
+$4.65M
5
STRO icon
Sutro Biopharma
STRO
+$2.06M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$6.35M
2
ADVM
Adverum Biotechnologies
ADVM
+$4.12M
3
ZYME icon
Zymeworks
ZYME
+$4.08M
4
IMTX icon
Immatics
IMTX
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Financials 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRME icon
26
Prime Medicine
PRME
$533M
$2.78M 0.58%
540,304
– –
DAWN
27
DELISTED
Day One Biopharmaceuticals
DAWN
$2.71M 0.57%
196,425
– –
IMTX icon
28
Immatics
IMTX
$1.29B
$2.3M 0.48%
198,000
-198,000
-50% -$2.23M
JANX icon
29
Janux Therapeutics
JANX
$982M
$1.89M 0.4%
45,052
-135,155
-75% -$6.35M
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
$1.38M 0.29%
202,348
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$1.06M 0.22%
154,664
– –
BOLT icon
32
Bolt Biotherapeutics
BOLT
$7.44M
$787K 0.16%
52,458
– –
LYRA
33
DELISTED
LYRA THERAPEUTICS INC
LYRA
$769K 0.16%
55,605
– –
ACRS icon
34
Aclaris Therapeutics
ACRS
$851M
$766K 0.16%
696,171
– –
VIRX
35
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$375K 0.08%
689,709
– –
ALLK
36
DELISTED
Allakos
ALLK
$172K 0.04%
172,089
– –
KRON
37
DELISTED
Kronos Bio
KRON
$96.9K 0.02%
78,131
– –
KLRS
38
Kalaris Therapeutics
KLRS
$99.7M
$59.6K 0.01%
3,580
– –
NUVB.WS
39
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$21.3K ﹤0.01%
133,333
– –
SRZNW icon
40
Surrozen Inc Warrant
SRZNW
$22.4K
$1.66K ﹤0.01%
99,999
– –
ADVM
41
DELISTED
Adverum Biotechnologies
ADVM
– –
-291,666
Closed -$4.12M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2024 Portfolio in Review

As of Q2 2024, Samsara BioCapital held 41 positions worth $478M, down 26% from $646M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $26.7M of net new capital in Q2 2024, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Climb Bio: 3,261,393 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $6.35M trimmed.

  • Samsara BioCapital's largest Q2 2024 buy was Climb Bio: 3,261,393 shares worth $23.2M.
  • Samsara BioCapital added most to CARGO Therapeutics in Q2 2024, an estimated $5.59M increase.
  • Samsara BioCapital's biggest Q2 2024 reduction was Janux Therapeutics, cutting an estimated $6.35M.
  • Samsara BioCapital fully exited Adverum Biotechnologies in Q2 2024, selling an estimated $4.12M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $478M portfolio in Q2 2024.
  • Samsara BioCapital opened 2 new positions and closed 1 in Q2 2024.
  • Samsara BioCapital's portfolio value fell 26% quarter-over-quarter to $478M.

Based on Samsara BioCapital's 13F filing for Q2 2024, filed 14 Aug 2024.